Compare FNWB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | RLYB |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 86.6M |
| IPO Year | 2012 | 2021 |
| Metric | FNWB | RLYB |
|---|---|---|
| Price | $11.01 | $16.12 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 38.2K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | 0.04 | ★ 6.16 |
| Revenue | $176,000.00 | ★ $858,000.00 |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $7.05 | $0.40 |
| 52 Week High | $12.52 | $17.57 |
| Indicator | FNWB | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 54.70 |
| Support Level | $9.37 | $15.60 |
| Resistance Level | $11.51 | $16.50 |
| Average True Range (ATR) | 0.37 | 0.46 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 4.59 | 27.42 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.